SCHEMBL112087

SCHEMBL112087

O=C(Nc1ccccc1)c1ccccc1N1CCN(C(=O)CNc2nccs2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 2/20 0.46
PTGS1 P23219 1/20 0.46
ALDH1A1 P00352 4/20 0.45
AURKA O14965 1/20 0.45
PIM1 P11309 1/20 0.45
CDK2 P24941 1/20 0.45
GSK3B P49841 1/20 0.45
TSHR P16473 1/20 0.45
ADORA2A P29274 1/20 0.44
CYP2C19 P33261 1/20 0.44
HSD17B10 Q99714 1/20 0.43
KMT2A Q03164 3/20 0.43
HPGD P15428 2/20 0.43
LMNA P02545 1/20 0.43
PKM P14618 1/20 0.43
GAA P10253 2/20 0.42
RAB9A P51151 2/20 0.42
GFER P55789 1/20 0.42
NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL111857 0.83 TRPV1 (0.47) ALDH1A1HSD17B10KMT2ARAB9ASMN1; SMN2
SCHEMBL3727130 0.82 CXCR3 (0.48) ALDH1A1TSHRKMT2ALMNARAB9A
SCHEMBL163411 0.77 PTGS2 (0.42) KMT2ALMNAGAARAB9AGFER
SCHEMBL3101424 0.76 YAP1 (0.54) ALDH1A1KMT2AHPGDGAARAB9A
SCHEMBL13077192 0.75 KMT2A (0.39) ALDH1A1TSHRHSD17B10KMT2ALMNA
SCHEMBL14665052 0.74 MAPT (0.49) ALDH1A1TSHRKMT2ALMNAGAA
SCHEMBL112182 0.74 CXCR3 (0.57) CYP1A2CYP3A4ALDH1A1ADORA2ACYP2C19
SCHEMBL115798 0.74 HTR1A (0.42) ALDH1A1TSHRKMT2ALMNAGFER
SCHEMBL111735 0.73 RAB9A (0.47) ALDH1A1KMT2ALMNARAB9ANPC1
SCHEMBL115274 0.73 CHEK1 (0.42) ALDH1A1TSHRHSD17B10KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2424858-B1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-05-14 EP disclosed
EP-2424858-B1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-05-14 EP disclosed
US-8362249-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-29 US disclosed
US-8362249-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-29 US disclosed
US-8362249-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-29 US disclosed
EP-2424858-A1 CXCR3 RECEPTOR ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2012-03-07 EP disclosed
WO-2010126851-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 WO disclosed
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-28 US disclosed
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-28 US disclosed
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS CXCR3, CXCR1, CXCR2 CYP1A2 2132/4885CYP3A4 2609/4885PTGS1 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.